Takeda’s diabetes drug fasiglifam, TAK 875, shines in Phase III

Takeda’s diabetes drug fasiglifam, TAK 875, shines in Phase III

Actavis is buying Warner Chilcott in an all-stock transaction valued at about $8.5B which would create the third-biggest specialty pharmaceutical company in the U.S

READ ALL THIS AT
http://www.pharmpro.com/news/2013/05/actavis-buying-warner-chilcott-85b-deal?et_cid=3264804&et_rid=519587661&linkid=http%3a%2f%2fwww.pharmpro.com%2fnews%2f2013%2f05%2factavis-buying-warner-chilcott-85b-deal
Actavis is buying Warner Chilcott in an all-stock transaction valued at about $8.5B which would create the third-biggest specialty pharmaceutical company in the U.S

Nigerian scientists have confirmed in clinical settings and in animal models that eating moderate quantities of bitter cola does not just enhance sexual activity but have clinically significant analgesic/anti-inflammatory effects in knee osteoarthritis patients

READ ALL AT
http://www.ngrguardiannews.com/index.php?option=com_content&view=article&id=121791:bitter-kola-boosts-libido-beats-osteoarthritis-researchers-confirm&catid=44:natural-health&Itemid=599

Transverse Myelitis PDFs and free access published articles

Transverse Myelitis PDFs and free access published articles 

Transverse myelitis is a neurological disorder caused by inflammation across both sides of one level, or segment, of the spinal cord. The segment of the spinal cord at which the damage occurs determines which parts of the body are affected.
Transverse myelitis
http://eradiology.bidmc.harvard.edu/LearningLab/central/Kaufman.pdf
Recurrent Myelitis Associated With Hepatitis C Infection
www.bcm.edu/neurology/pdf/poster_other_RecurrentMyelitis.pdf
Neuro MRI Ordering Guide
MRI_Ordering_Guide2_1_.pdf
General Information Regarding MS
General_information_regarding_ms.pdf
NMO-IgG predicts the outcome of recurrent optic neuritis
NMO-IgG Rose-Innes_article1.pdf
Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis
Patrick Waters, PhD; Sven Jarius, MD; Edward Littleton, MBBS, DPhil; Maria Isabel Leite, MD etal
Aquaporin-4 Antibodies in Neuromyelitis.pdf
Transverse myelitis – Case study
Transverse myelitis.pdf
Diagnosis of Transverse Myelitis: An Evaluation of the factors leading to Spinal Dysfunction
Including a Review of one patients’ experience
Diagnosis of Transverse Myelitis.pdf
Imaging Sciences Interesting Cases
Jacinto Camarena III, MD
IS_Case12.pdf
50 Free scholarly articles on Transverse myelitis

1. Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices.
2. Urinary retention in immunocompetent patient: acute transverse myelitis.
3. Acute transverse myelitis in Buenos Aires, Argentina. A retrospective cohort study of 8 years follow up.
4. Rhabdomyolysis, acute kidney injury and transverse myelitis due to naive heroin exposure.
5. Longitudinally extensive transverse myelitis: a catastrophic presentation of a flare-up of systemic lupus erythematosus.
6. Primary HIV infection with acute transverse myelitis.
7. H1N1 vaccine-related acute transverse myelitis.
8. Acute transverse myelitis following vaccination against H1N1 influenza: a case report.
9. Acute transverse myelitis and acute motor axonal neuropathy developed after vaccinations against seasonal and 2009 A/H1N1 influenza.
10. Optical coherence tomography evaluation of retinal nerve fiber layer in longitudinally extensive transverse myelitis.
11. Clinical analysis of 6 cases of systemic lupus erythematosus complicated by transverse myelitis.
12. Mycobacteria infection in incomplete transverse myelitis is refractory to steroids: a pilot study.
13. Acute transverse myelitis associated with dengue viral infection.
14. Idiopathic acute transverse myelitis in children: an analysis and discussion of MRI findings.
15. Longitudinally extensive transverse myelitis following vaccination with nasal attenuated novel influenza A(H1N1) vaccine.
16. Transverse myelitis associated with chronic viral hepatitis C.
17. High-level cervical spinal cord stimulation used to treat intractable pain arising from transverse myelitis caused by schistosomiasis.
18. Acute transverse myelitis: treatment of pain.
19. Transverse myelitis associated to HCV infection.
20. Acute transverse myelitis: a clinical review and algorithm for diagnostic intervention.
21. Priapism in infantile transverse myelitis.
22. Transverse myelitis spectrum disorders.
23. Transverse myelitis as a presenting feature of late onset systemic lupus erythematosus.
24. Acute transverse myelitis and Guillain-Barre overlap syndrome following influenza infection.
25. Diffusion tensor imaging in idiopathic acute transverse myelitis.
26. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis.
27. Transverse myelitis due to human herpesvirus 6.
28. Subacute transverse myelitis with Lyme profile dissociation.
29. Transverse myelitis associated with systemic lupus erythematosus.
30. Idiopathic recurrent transverse myelitis with syringomyelia: a case report.
31. Acute transverse myelitis at the conus medullaris level after rabies vaccination in a patient with Behçet’s disease.
32. Transverse myelitis in a patient with severe lupus nephritis: a case report.
33. Transverse myelitis in 2 patients with Bartonella henselae infection (cat scratch disease).
34. Transverse myelitis caused by varicella zoster: case reports.
35. Transverse myelitis in systemic lupus erythematosus.
36. Acute transverse myelitis following typhoid vaccination.
37. Transverse myelitis following spinal anesthesia.
38. Neuromyelitis optica IgG status in acute partial transverse myelitis.
39. Neurosyphilis manifesting as spinal transverse myelitis.
40. Etanercept induced multiple sclerosis and transverse myelitis.
41. Acute transverse myelitis following hepatitis E virus infection.
42. Transverse myelitis due to trypanosomiasis in a middle aged Tanzanian man.
43. Rapid recovery from acute transverse myelitis in an elite female swimmer.
44. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. 
45. Acute transverse myelitis and hepatitis C virus.
46. Transverse myelitis and chronic urticaria in systemic lupus erythematosus. Case report.
47. Primary biliary cirrhosis complicated by transverse myelitis in a patient without Sjögren’s syndrome.
48. Transverse myelitis in immunocompetent children.
49. Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.
50. Acute transverse myelitis: important role of biology in diagnosis.

Transverse Myelitis in ppt format

Organic India launches single ingredient Moringa products in US

Organic India launches single ingredient Moringa products in US  
 CLICK HERE

SciClone Gains China Rights to Zensun’s Heart Failure Drug

may19, 2013

SciClone Pharma in-licensed China rights to a heart failure drug from Zensun (Shanghai) Science & Technology Co. SciClone, which is headquartered in the US, usually markets western drugs in China. This time, the company has acquired a China-developed drug for China.

 

The deal gives SciClone exclusive rights to market Neucardin™, a novel treatment for chronic heart failure, in China, Hong Kong and Macau. Zensun filed for approval of Neucardin with the CFDA last year

NEUCARDIN^TM is a genetically engineered recombinant peptide fragment of neuregulin-1 (β2a isoform). It is expressed in E.coli , lyophilized for storage and used for the treatment of moderate to severe heart failure.

Mechanisms : It has been shown that neuregulin-1 is importantly involved in development, differentiation and function of myocardial cells. Based on research on molecular and cellular level, Zensun found that NEUCARDINTM couldattenuate myofibrillar disarray in impaired myocardial cells and strengthen the intercalated disc connections between them. In addition, in vivo administration of NEUCARDINTM greatly reduced myocardial cell damage induced by ischemia, hypoxia or viral infection, allowing repair of sarcomere structure, with improvement in cardiac performance, hemodynamics and survival.

Indications : NEUCARDIN^TM is indicated for the treatment of patients with intermediate to advanced heart failure and dilated cardiomyopathy.

Pharmacological Action : Using various animal models, including (1) rat sub-acute and chronic heart failure, (2) mouse viral myocarditis, (3) rat toxic myocarditis induced by adriamycin, and (4) dog congestive heart failure caused by constriction of inferior venue cava, it has been demonstrated that NEUCARDIN^TM improves impaired myocardial structure, decreases the extent of ischemia injury, and improves heart function and hemodynamics. This results in enhanced survival in these animal models.

Safety : Safety pharmacology studies indicate that NEUCARDIN^TM has no adverse effects on cardiovascular or respiratory system function in normal monkeys. Acute toxicity studies in mice showed that the minimum fatal dose was 3000 times the clinical equivalent dose. Safety evaluations in monkeys after administration of multiple doses of NEUCARDIN^TM revealed that a high dosage (above the therapeutic dose) could cause some local microcapillary vessel leakage, but no significant side effects had been found with doses in low to moderate ranges, indicating a safe therapeutic dosage range.

 

ALL ABOUT MOLECULES

READ ALL AT
https://sites.google.com/site/anthonycrastomolecules/